Inhibrx Biosciences公司:Inbrx-106联合帕博利珠单抗确认客观缓解率达44.0%,显著优于单药21.4%

美股速递
May 11

Inhibrx Biosciences公司公布了其候选药物Inbrx-106与帕博利珠单抗联合疗法的积极数据。结果显示,该联合方案取得了44.0%的确认客观缓解率,而单独使用帕博利珠单抗的对照组,其确认客观缓解率仅为21.4%。这一数据对比凸显了联合疗法在疗效上的显著优势。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10